On May 23, 2024, Grey Wolf Therapeutics closed the transaction. On the same day, company has raised $50 million in second and final tranche, led by new investor, ICG Life Sciences Fund, a fund managed by Intermediate Capital Group plc, bringing total funding raised in the transaction to $99 million. The tranche included participation from existing investors, Pfizer Venture Investments LLC, Andera Partners, Canaan Management, Inc., Earlybird Venture Capital GmbH & Co.

KG, Oxford Science Enterprises and British Patient Capital Limited. As part of the tranche, Tracy Weightman from Intermediate Capital Group plc joined company's board of directors. The tranche was oversubscribed.